Clinical Research Directory

Inclusion Criteria: 1. Signed informed consent must be obtained prior to participation in the study 2. Documented diagnosis of CHD prior to screening, including acute coronary syndrome (ACS) and chronic coronary syndrome (CCS) 3. Aged ≥18 years at randomization 4. Despite maximally tolerated statin therapy for ≥4weeks stable using prior to screening, LDL-C result at screening not at goal (≥1.8 mmol/L). The maximum tolerated dose of statins also includes patients with statin intolerance or contraindication. Exclusion Criteria: 1. Received inclisiran during the 2 years prior to the screening. 2. Received proprotein convertase subtilisin-kexin type 9 (PCSK9) mabs during the 3 months prior to screening. 3. Participating in an interventional trial at enrollment 4. Having severe liver disorder (Child-Pugh class C) 5. Any other condition that may put the participant at significant risk if the participant participate in the current study, according to investigator's (or delegate's) judgment. Other protocol-defined inclusion/exclusion criteria may apply.